Pharmalot.. Pharmalittle.. Good Morning and Nice to See You Again
Hello, everyone, and welcome back. It’s wonderful to see you again. After a brief hiatus, we are returning as part of Stat, which is devoted to health, medicine and life sciences, and will launch in a few short weeks. So think of this as Pharmalot XR, since we will re-emerge in stages and migrate to the new Stat site at that time. Meanwhile, please forgive any technical glitches that may arise as we grapple with the transitions. Now, though, the time has come to get cracking. So please join us we reach for that treasured cup of stimulation and dig in for a busy day. As always, we have assembled some tidbits to get you going. Hope you conquer the world and do stay in touch. Remember, we enjoy juicy tales and secret documents…
Democrats on the House oversight committee want a subpoena issued to Valeant Pharmaceuticals; Hillary Clinton is proposing that brand-name drug makers should fund their generic rivals; Hedge fund manager Kyle Bass was given a green light to try to profit from efforts to wipe out drug patents and the FDA criticized a letter that was sent by several U.S. Senators who themselves chastised the agency for its policy allowing OxyContin prescriptions for youngsters